BioSpace News Archive

Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers, reported financial results for the second quarter 2022 and provided an operational update.

Tarsus Pharmaceuticals, Inc., whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for eye diseases, announced financial results for the second quarter ended June 30, 2022, and recent business achievements.

Avalo Therapeutics, Inc. announced that on August 8, 2022, Steven Boyd and Keith Maher, MD, both of Armistice Capital, LLC, the investment manager to Armistice Capital Master Fund Ltd., notified the Board of Directors of Avalo Therapeutics, Inc. that they have resigned from their positions on the Board.

Eledon Pharmaceuticals, Inc. reported its second quarter 2022 operating and financial results and reviewed recent business highlights.

LianBio, a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.

Ventyx Biosciences, Inc. announced that it will report topline results from the Phase 1 trial of its selective, allosteric TYK2 inhibitor VTX958 as well as financial results for the second quarter ended June 30, 2022, after market close on August 15, 2022.

TFF Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, reported financial results for the second quarter of 2022 and provided an update on recent corporate and clinical developments.

Mustang Bio, Inc. announced financial results and recent corporate highlights for the second quarter ended June 30, 2022.

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, reported second quarter 2022 financial results and provided a 4D-310 program update.

Brickell Biotech, Inc., a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, announced financial results for the second quarter ended June 30, 2022 and provided a corporate update.